Navigation Links
Kinex Pharmaceuticals Announced that the U.S. Food and Drug Administration has Granted Orphan Drug Status to KX02 for the Treatment of Gliomas
Date:12/4/2013

BUFFALO, N.Y., Dec. 4, 2013 /PRNewswire/ -- Kinex Pharmaceuticals announced today that they have received Orphan Drug designation for KX02 for the treatment of gliomas, which are the most common and aggressive form of brain cancer.  Orphan drug status qualifies Kinex for seven years of exclusivity after formal marketing approval, as well as further development incentives. KX02, a dual src/pre-tubulin inhibitor, is a small molecule drug that has shown potent inhibitory activity against a broad panel of brain tumor cell lines, including those that are resistant to Temozolomide (T98G), the most widely used chemotherapy for the treatment of malignant glioma.  In a well-established brain tumor animal model, KX02 consistently clears brain tumors after 4 weeks of therapy, in 30-60% of treated animals. These studies showed that KX02 induced more necrosis compared to Temodar, and also generated an immune response to the glioblastoma tumor cells. Pharmacokinetic studies showed that KX02 is absorbed orally and has 76% penetration into brain tissue from plasma. 

Dr. David Hangauer, Chief Scientific Officer of Kinex stated, "Receiving Orphan Drug Status for KX02 speaks to the need for new treatment options for patients with gliomas. KX02 is a novel compound with good potential for these patients in terms of generating a durable immune response to tumor cells in mice that allow the animals to live to their full life expectancy without tumor recurrence or further drug treatment.  We are looking forward to moving this novel compound into the clinic."

"This is an important regulatory milestone for Kinex," stated Dr. Lyn Dyster, Senior VP of Operations at Kinex.  "The orphan drug designation will facilitate our goal of developing KX02 as a potentially new and effective treatment for patients with gliomas. The standard treatment for glioblastoma cons
'/>"/>

SOURCE Kinex Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Kinex Announces First Patient Dosed in Phase Ib Study of Oraxol, an Orally Dosed Paclitaxel
2. Hanmi Pharmaceuticals to Assign the Rights to Five New Territories to Kinex as Part of the Orascovery Program Strategic Plan
3. Dr. David Hangauer, Chief Scientific Officer and Co-Founder, commits his career to Kinex Pharmaceuticals
4. Kinex Receives Research Support from the Hong Kong Innovation and Technology Commission (ITC)
5. Kinex Announces that the US FDA Allows their IND for Oraxol, an Oral Form of Paclitaxel that is in Phase II Clinical Trials in Korea, to Begin Clinical Trials in the US
6. Kinex Pharmaceuticals Will Take the Lead in the Orascovery Program Development in China
7. Kinex Announces that the US FDA Allows their IND to Begin KX02 Clinical Trials
8. Kinex Pharmaceuticals and Zenith Technology Corporation announce the execution of a collaborative licensing agreement
9. Kinex Pharmaceuticals Chief Scientific Officer, Dr. David Hangauer, named the American Cancer Societys 2013 Honoree for its Cuisine for a Cure event
10. Hanmi and Kinex Announced Korean FDA Allowance of the KX01 IND Application
11. Kinex Pharmaceuticals Appoints Mr. Patrick Gallagher Vice President of Business Development and Investor Relations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... DIEGO and CARDIFF-BY-THE-SEA, Calif. ... Inc. (NASDAQ: SRNE ;  Sorrento), an ... associated pain, and Conkwest, Inc., a privately-held immuno-oncology ... Natural Killer (NK) cell-line based therapy, announced today ... agreement to jointly develop next generation CAR-TNK™ (pronounced ...
(Date:12/19/2014)... 18, 2014  Decision Resources Group finds that the ... will increase to a value of over ... by expansion in the large direct energy device market. ... increasingly adopted due to the advantages they offer and ... findings from Decision Resources Group,s coverage of the U.S. ...
(Date:12/19/2014)... KANSAS CITY, Kan. , Dec. 18, 2014 ... PETX ), a biopharmaceutical company focused on ... for companion animals, today announced positive results from ... company,s innovative drug for treating pain in dogs ... demonstrated improvements in pain assessment scores that were ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
... University Medical Pharmaceuticals, which specializes in developing and distributing ... to the mass market, announced today that it has ... , Mr. Ten brings 28 years of ... luxury and consumer packaged goods industry. At University ...
... Inc., a company leading the scientific research of neurogenesis ... identify novel pathways for the treatment of central nervous ... Scolnick from the Broad Institute of MIT and Harvard ... to its scientific advisory board. The appointees join BrainCells, ...
Cached Medicine Technology:University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales 2University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales 3BrainCells Inc. Broadens Scientific Advisory Board Adding Drs. Edward Scolnick and David Holtzman 2BrainCells Inc. Broadens Scientific Advisory Board Adding Drs. Edward Scolnick and David Holtzman 3
(Date:12/20/2014)... 20, 2014 Angeldress.co.uk, the distinguished wedding ... for worldwide dress fans. The company has recently updated ... information. For the holiday season, Angeldress Blog ... wedding apparel. , Angeldress.co.uk prides itself in offering a ... of service. All the company’s outfits are very carefully ...
(Date:12/20/2014)... York, NY (PRWEB) December 20, 2014 The ... has caused quite a stir, not only in Hollywood, but ... on December 18th , the ripples of that attack are ... executives’ very jobs at risk. But they are not ... correspondences exposed could be in for some embarrassing times ahead, ...
(Date:12/20/2014)... December 20, 2014 Xarelto bleeding ... suffered uncontrollable bleeding and other serious side effects ... District of Louisiana for coordinated pretrial proceedings, Wright & ... Litigation (JPML) issued an order Friday to transfer 21 ... in 22 federal courts to the Louisiana district court ...
(Date:12/20/2014)... Today, Balfleet.com, one of the most outstanding dressmakers in ... on its Mother of the Bride Dresses ... bride dresses from Balfleet.com feature gorgeous looks and delicate ... pride in providing high quality dresses to its clients ... on our mother of the bride dresses, and we ...
(Date:12/19/2014)... 2014 Sweetdressy.com , a leading ... its newest selection of cheap prom dresses for ladies ... in the world and clients can buy these dresses ... prom dresses feature cool cuts and delicate craftsmanship, and ... the middle-end market. Discount shipping costs are available for ...
Breaking Medicine News(10 mins):Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2
... Actress and best-selling author,Jenny McCarthy has established herself ... autism cure and advocate for nutritional regimens to ... Health Trax(TM) (GHT) flagship,specialty probiotic product, ThreeLac(TM), into ... in her book Louder than,Words: A Mother,s Journey ...
... fails to ease symptoms, but old drug offers new hope ... step forward, one step back in the search for treatments ... the July 19 issue of The Lancet , an ... a second report, a once-promising vaccine failed to prevent the ...
... Women Veterans, WASHINGTON, July 18 Dr. Paula ... Traumatic,Stress Disorder (PTSD), received the 3rd annual Ladies Home ... women veterans., "Dr. Schnurr,s contribution to veterans is ... who have borne the battle,",said Secretary of Veterans Affairs ...
... the earliest events occurring immediately upon infection with HIV-I ... the immune system earlier than was previously understood. According ... the window of opportunity for successful intervention may be ... after transmission, as researchers had previously believed. , Appearing ...
... patients develop resistance to chemotherapy drugs, sometimes abruptly, after ... working well to reduce tumors or hold them in ... result when this occurs is all too familiar: patients ... become resistant. , A team of researchers at Cold ...
... Proposed Acquisition to Strengthen Existing Therapeutic Focus Through ... Extending the ... 18 /Xinhua-PRNewswire-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: BJGP; "BMP Sunstone"; ... Co., Ltd. ("Sunstone") has signed a non-binding letter of,intent ...
Cached Medicine News:Health News:Global Health Trax Joins Fight Against Autism With Jenny McCarthy and Generation Rescue 2Health News:Alzheimer's Research Brings Progress, Setbacks 2Health News:Alzheimer's Research Brings Progress, Setbacks 3Health News:Alzheimer's Research Brings Progress, Setbacks 4Health News:HIV conquers immune system faster than previously realized 2Health News:HIV conquers immune system faster than previously realized 3Health News:CSHL scientists correlate enzyme expression levels with chemotherapy drug response 2Health News:CSHL scientists correlate enzyme expression levels with chemotherapy drug response 3Health News:CSHL scientists correlate enzyme expression levels with chemotherapy drug response 4Health News:BMP Sunstone Signs Letter of Intent to Acquire Shengda Pharmaceutical Co. 2Health News:BMP Sunstone Signs Letter of Intent to Acquire Shengda Pharmaceutical Co. 3
... Bledsoe Sport & Sport Max patellofemoral knee ... and/or collateral injuries. Patients with minor knee ... can benefit from added support to prevent ... designs to provide the right kind of ...
... Brace gives fracture treatment patients maximum support ... brace features the the Bledsoe Multi-Centric Hinge, ... and positively locks at any angle within ... slots, the Bledsoe Multi-Centric Hinge anatomically tracks ...
... The Bledsoe Revolution ... for speed fitting under ... frees the surgeon or ... time-consuming post-op fitting and ...
The Bledsoe Post-Op Knee Brace is designed to provide maximum protection without sacrificing comfort and quick, easy application....
Medicine Products: